A Multicenter, Open-Label, Treatment Extension Trial to Evalaute the Long-Term Safety and Tolerability of Mesalamine [mesalazine] Pellet Formulation.
Phase of Trial: Phase III
Latest Information Update: 15 Dec 2017
At a glance
- Drugs Mesalazine (Primary)
- Indications Ulcerative colitis
- Focus Adverse reactions
- Sponsors Salix Pharmaceuticals
- 29 Dec 2009 Status changed from discontinued to completed as reported by ClinicalTrials.gov.
- 29 Sep 2009 New trial record.